Armata Pharmaceuticals, Inc.

For the period ended Jun 11, 2026. Filed Apr 27, 2026.

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Jun 11, 2026 · Filed Apr 27, 2026

ARMP$3.51+17.0%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Pay versus Performance Table


(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)
					Average		Value of
					Summary		Initial Fixed
	Summary				Compensation		$100
	Compensation				Table Total		Investment
	Table Total				for Non-PEO	Average	Based on
	for Principal		Summary		Named	Compensation	Total
	Executive	Compensation	Compensation	Compensation	Executive	Actually Paid	Shareholder
	Officer	Actually Paid	Table Total	Actually Paid	Officers	to Non-PEO	Return	Net Income(7)
	(“PEO”) 1(2)	to PEO 1(3)	for PEO 2(2)	to PEO 2(3)	(“NEOs”)(4)	NEOs(5)	(“TSR”)(6)	(Thousands)
Year(1)	($)	($)	($)	($)	($)	($)	($)	($)
2025	1,249,889	4,238,979	—	—	673,173	1,185,461	113	(173,799)
2024	1,843,527	1,004,531	—	—	636,330	493,180	33	(18,916)
2023	1,133,931	1,421,104	634,140	578,496	316,267	357,361	58	(69,045)

(1)	We are a smaller reporting company pursuant to Rule 405 of the Securities Act of 1933, and as such, we are only required to include information for the past three fiscal years in this table.

(2)

The dollar amounts reported in column (b) for the fiscal year 2025 is the amount of total compensation reported for Dr. Birx (“PEO 1”). The dollar amounts reported in column (b) for the fiscal year 2024 is the amount of total compensation reported for Dr. Birx (“PEO 1”). The dollar amounts reported in columns (b) and (d) for the fiscal year 2023 is the amounts of total compensation reported for Dr. Birx (our Chief Executive Officer since July 10, 2023) (“PEO 1”) and Dr. Brian Varnum (our Chief Executive Officer until July 10, 2023) (“PEO 2”), respectively. Refer to “Executive Compensation - Summary Compensation Table” above.

(3)

The dollar amounts reported in columns (c) and (e) represent the amount of “compensation actually paid” to Dr. Birx and Dr. Varnum, respectively, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual amount of compensation earned by or paid to Dr. Birx and Dr. Varnum during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the adjustments made to Dr. Birx’s and Dr. Varnum’s total compensation for each year to determine the compensation actually paid are shown in the “Adjustments to Compensation Actually Paid” table below.

(4)

The dollar amounts reported in column (f) represent the average of the amounts reported for our Company’s named executive officers (other than Dr. Birx and Dr. Varnum) as a group (“NEOs”) in the “Total” column of the Summary Compensation Table in each applicable year. The names of each of the NEOs included for purposes of calculating the average amounts in each applicable year are as follows: (i) for 2025, Pierre Kyme and David House; (ii) for 2024, Pierre Kyme, David House, Mina Pastagia, and Richard Rychlik; and (iii) for 2023, Richard Rychlik, Mina Pastagia and Erin Butler.

(5)

The dollar amounts reported in column (g) represent the average amount of “compensation actually paid” to the NEOs as a group, as computed in accordance with Item 402(v) of Regulation S-K. The dollar amounts do not reflect the actual average amount of compensation earned by or paid to the NEOs as a group during the applicable year. In accordance with the requirements of Item 402(v) of Regulation S-K, the adjustments made to the average total compensation for the NEOs as a group for each year to determine the average compensation actually paid are shown in the “Adjustments to Compensation Actually Paid” table below.

(6)

Cumulative total shareholder return (“TSR”) is calculated by dividing the sum of the cumulative amount of dividends for the measurement period, assuming dividend reinvestment, and the difference between our Company’s share price at the end and the beginning of the measurement period (December 31, 2021) by our Company’s share price at the beginning of the measurement period. No dividends were paid on stock or option awards in 2023, 2024 or 2025.

(7)	The dollar amounts reported represent the amount of net income (loss) reflected in our audited financial statements for the applicable covered year.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.